Ultra-Sensitive Cancer Monitoring from Plasma cfDNA Using Genome-Wide Sequencing
This Nature Medicine study demonstrates that genome-wide integration of tumor mutations in plasma cell-free DNA enables ultra-sensitive detection of minimal residual disease and early recurrence—down to tumor fractions as low as 10⁻⁵. By using high-quality cfDNA isolated with the Mag-Bind® cfDNA Kit, researchers ensured optimal fragment recovery and consistency, supporting the reliable whole-genome sequencing workflows that made this breakthrough in cancer monitoring possible.
Ultra-Sensitive Cancer Monitoring from Plasma cfDNA Using Genome-Wide Sequencing Read More »
